Unlocking More Blood Cancer Insights,
Accelerate Your Path To Precision Oncology.

EHA 2022 Virtual Symposium Presentations

Watch our on-demand virtual symposium (EHA 2022) to learn how we can help simplify your path to answers in the study of myeloid and lymphoid cancer.

 

Speed And Simplicity: Molecular Profiling Of Myeloid Malignancies Using Next Generation Sequencing

Presenter: Marianne Grantham

Head of Cytogenetics and Molecular Haematology,
Barts Health NHS Trust, UK

The impact of fast NGS molecular profiling in myeloid malignancy research

Presenter: Dr. Dolors Colomer

Head of Hematopathology
Hospital Clinic, IDIBAPS, University of Barcelona, Spain

Adopting rapid NGS for the study of Haemato-oncology malignancies

Presenters: Dr Lihui Wang, Molecular Lead, HODS

Dr. Geetha Menon Clinical Director, HODS

Cheshire & Merseyside Cancer Network, Liverpool, UK

Oncomine Myeloid Assay GX v2

The first myeloid genomic profiling solution that can deliver an NGS report, covering all key DNA and RNA targets, in as little as one day on the Ion Torrent Genexus System.

Oncomine Pan-Clonality Assays

Advanced NGS solutions that can sequence multiple B- and T-cell receptor targets in a single reaction for highly sensitive and specific clone detection.

Oncomine Myeloid MRD NGS Assay

Highly sensitive NGS test for measurable residual disease (MRD) assessment that can identify mutations occurring at very low frequencies.

 

Absolute Q dPCR Liquid Biopsy Assays

Applied Biosystems Absolute Q Liquid Biopsy dPCR Assays offer a precise, cost-effective, and rapid method for monitoring response and resistance to treatment by testing for relevant cancer-driver and therapy-resistant mutations.

 

Explore our full haemato-oncology product portfolio

 

Contact Us

Request a quote or personal demonstration from a Thermo Fisher Scientific representative.

 

 

For Research Use Only.  Not for use in diagnostic procedures.